Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine’s Antidepressant Action
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The prevailing hypothesis of ketamine’s unique antidepressant effects implicates N-methyl-d-aspartate receptor (NMDAR) inhibition-dependent enhancement of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated transmission, activation of intracellular signalling pathways and increased synaptogenesis. Recently, however, a seminal study by Zanos et al. directly challenged the NMDAR hypothesis of ketamine with the claim that an active ketamine metabolite, (2R,6R)-hydroxynorketamine, devoid of NMDAR binding properties or key side effects of its parent compound, is both necessary and sufficient for ketamine’s antidepressant effects in rodents. However, following these encouraging initial findings, one preclinical study failed to replicate the antidepressant effects of (2R,6R)-hydroxynorketamine (HNK), while others have questioned the metabolite’s contribution to ketamine’s therapeutic effects or argued against rejecting the NMDAR hypothesis of ketamine action. In light of these potentially paradigm-shifting, but highly controversial, findings, this review will summarise and critically evaluate the evidence for and against the NMDA receptor hypothesis of ketamine action, with a particular focus on (2R,6R)-HNK and the implications of its discovery for understanding ketamine’s mechanism of action in depression. Ultimately, uncovering the molecular mechanisms underlying the therapeutic effects of ketamine and possibly (2R,6R)-HNK, will aid the development of novel and more efficacious antidepressant agents so urgently needed to address a major public health concern, and could hold potential for the treatment of other stress-related psychopathologies, including bipolar disorder, post-traumatic stress disorder and suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 1×
“Another general limitation relates to the prevalence of MDD in women, which is approximately two times higher than in men; yet despite this important sex difference, preclinical research investigating the mechanisms underlying ketamine’s, and more recently (2R,6R)-HNK’s, antidepressant effects have been conducted almo…”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Mechanisms of stress in the brain
McEwen, B. S., Bowles, N. P., Gray, J. D., Hill, M. N., Hunter, R. G., Karatsoreos, I. N., & Nasca, C. (2015) · Nature Neuroscience · doi:10.1038/nn.4086 · Cited by 1,386
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 8×
“Although the molecular target(s) of (2R,6R)-HNK have not been defined, studies have implicated increased AMPAR-mediated synaptic transmission, BDNF and protein synthesis,(14,57) which seem to represent points of convergence with ketamine.(10,22,28) It is also important to consider other, unique effects of (2S,6S;2R,6R…”
BackgroundInfluentialBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 3×
“Regardless of the exact trigger, ketamine initiates a long-term potentiation (LTP)-like process leading to synaptic protein synthesis, AMPAR subunit upregulation and synaptogenesis in the HPC and PFC.(28,36,37) Thus, it is thought to induce an NMDAR inhibition-dependent form of synaptic plasticity, reversing the stres…”
BackgroundLong-term depression in the CNS
Collingridge, G. L., Peineau, S., Howland, J. G., & Wang, Y. T. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2867 · Cited by 926
Self-citationR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“However, to date, ketamine is the only NMDAR antagonist to consistently demonstrate antidepressant efficacy in multiple trials.(6,14,39) In addition, while ketamine is usually administered as a racemic mixture in the clinic, R-ketamine has more potent and sustained antidepressant properties in rodents compared to S-ke…”
BackgroundStress, depression, and anhedonia: caveats concerning animal models
Anisman, H., & Matheson, K. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.007 · Cited by 569
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422 · cited 6×
“Although the molecular target(s) of (2R,6R)-HNK have not been defined, studies have implicated increased AMPAR-mediated synaptic transmission, BDNF and protein synthesis,(14,57) which seem to represent points of convergence with ketamine.(10,22,28) It is also important to consider other, unique effects of (2S,6S;2R,6R…”
BackgroundInfluentialZhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 2×
“In stark contrast to classical antidepressants, ketamine possesses rapid antidepressant effects that are evident within an hour, peak around 24 h and can last up to 1–2 weeks after infusion.(7,9) Unfortunately, the widespread clinical use of ketamine for depression is limited by psychotomimetic side effects,”
BackgroundMiller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358 · cited 4×
“Importantly, he emphasises that in their study the ‘sustained’ antidepressant effects of ketamine and (2R,6R)-HNK are assessed at 24 h after injection; however, authors did not test for a longer-lasting antidepressant effect (seven days), as is commonly done in studies of ketamine.15 Another inconsistency in the Zanos…”
BackgroundInfluentialStress, anxiety, and dendritic spines: What are the connections?
Leuner, B., & Shors, T. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.021 · Cited by 284 · cited 1×
“areas implicated in MDD, effects believed to underlie the antidepressant response to ketamine.(13,24,38) Together, these studies have significantly expanded on the simplified NMDAR inhibition hypothesis of ketamine action, supporting the crucial involvement of AMPARs and synaptogenic pathways in mediating ketamine’s a…”
BackgroundZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Sex differences in the antidepressant-like effects of ketamine
Carrier, N., & Kabbaj, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.009 · Cited by 251
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228 · cited 9×
“Although ketamine’s therapeutic effects were long attributed to direct NMDAR inhibition, emerging clinical and preclinical data cast significant doubt on the oversimplified NMDAR inhibition hypothesis of ketamine’s action in depression.(13) Most recently, a seminal Nature paper by Zanos et al.”
BackgroundMethodSelf-citationKETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016) · Depression and Anxiety · doi:10.1002/da.22501 · Cited by 206
Carreno, F. R., Donegan, J. J., Boley, A. M., Shah, A., DeGuzman, M., Frazer, A., & Lodge, D. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.176 · Cited by 205
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200 · cited 4×
“BDNF, mTOR).(26,30) Consistent with a direct action on PNs, selective genetic deletion of the NMDAR subunit GluN2B from cortical PNs both mimics and occludes ketamine’s antidepressant effects in mice, as well as enhancing protein synthesis and AMPAR-mediated transmission in the PFC.”
BackgroundInfluentialEffects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180 · cited 9×
“almost 100% with 50 mM ketamine), and only this higher dose was found to induce a decrease in eEF2 kinase phosphorylation.(16) Based on these results, they conclude that similar to its parent compound, (2R,6R)-HNK is an open-channel NMDAR antagonist, which converges onto the same intracellular signalling pathways prev…”
BackgroundResultInfluentialMoaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Yang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173 · cited 1×
“This, in turn, results in the activation of downstream signalling pathways, particularly those involving brain-derived neurotrophic factor (BDNF) release and activation of the mammalian target of rapamycin (mTOR).(5,22,28,29) Under the second hypothesis (Figure 1(b)), direct antagonism of NMDARs on PNs by ketamine at…”
BackgroundSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157
Zhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04198.x · Cited by 137 · cited 5×
“Intriguingly, clinical studies suggest that the conversion of (R,S)-Ketmay be enantioselective, as significantly higher plasma concentrations of (2R,6R)-HNK relative to (2S,6S)-HNK are observed post-ketamine administration.(42,44) One study in rats reports that sub-chronic ketamine dosing increased the clearance of (R…”
BackgroundInfluentialKetamine enantiomers in the rapid and sustained antidepressant effects
Muller, J., Pentyala, S., Dilger, J., & Pentyala, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316631267 · Cited by 122
Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., O’Loughlin, K., Torjman, M. C., Bernier, M., & Wainer, I. W. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000285 · Cited by 115
Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86 · cited 1×
“Importantly, this hypothesis is supported by clinical reports of a link between antidepressant response to ketamine and plasma D-serine concentrations, showing that responders had significantly lower pre-treatment D-serine levels and ketamine further resulted in significant reductions over the next 24 h, attributed to…”
ResultSingh, N. S., Rutkowska, E., Plazinska, A., Khadeer, M., Moaddel, R., Jozwiak, K., Bernier, M., & Wainer, I. W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149499 · Cited by 23 · cited 8×
“It is also important to consider other, unique effects of (2S,6S;2R,6R)-HNK such as a7-nAchR antagonism(41) and attenuation of Dserine levels, which could possibly lead to an indirect inhibition of NMDAR function.(64) Therefore, (2R,6R)HNK could contribute to ketamine’s unique ability to increase the AMPA to NMDA rece…”
BackgroundInfluential
Cited by
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Self-citationAbdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
Self-citationHydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
“…2019b; Chou et al., 2018; Highland et al., 2019; Pham et al., 2018; Fukumoto et al., 2019; Lumsden et al., 2019; Rahman et al., 2020; Yokoyama et al., 2020), leading to a growing interest in understanding their biologic activities (Abdallah, 2017; Aleksandrova et al., 2017; Gould et al., 2019).”
BackgroundAleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2020) · Molecular Brain · doi:10.1186/s13041-020-00627-z · Cited by 85
Self-citation
Metadata
- Authors
- Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G.
- Venue
- Chronic Stress
- Publisher
- SAGE Publications
- Published
- 2017-02
- Volume
- 1
- ISSN
- 2470-5470 (ISSN-L)
- OpenAlex
- W2775504840
- Cited by
- 20
- References
- 34
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.